Drug Profile
Ezetimibe/rosuvastatin calcium - Merck Sharp and Dohme
Alternative Names: Ezetimibe 10mg/Rosuvastatin Ca 20mg; HCP 1306; HCP-1903; ID1801; MK 0653H; RosuzetLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Developer Hanmi Pharmaceutical; Merck Sharp & Dohme
- Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypercholesterolaemia
- Registered Hyperlipoproteinaemia type IIa
- Phase III Hypertension
Most Recent Events
- 04 Dec 2019 IlDong Pharmaceutical plans a phase I pharmacodynamics/pharmacokinetic interaction and safety study in Healthy volunteers (ID-VARE-101; NCT04185090)
- 16 Jul 2019 Phase-III clinical trials in Hypercholesterolaemia (Combination therapy) in South Korea (PO) (NCT04074551)
- 16 Jul 2019 Phase-III clinical trials in Hypertension (Combination therapy) in South Korea (PO) (NCT04074551)